The FDA has issued more than 200 complete response letters, which detail reasons for non-approval of drug applications.

In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.